L-Prolinamide, 2,2'-[[(2S,5S)-1-[4-(1,1-dimethylethyl)phenyl]-2,5-pyrrolidinediyl]di-4,1-phenylene]bis[N-(methoxycarbonyl)-L-valyl-
Title | Journal |
---|---|
Resistance Mechanisms in Hepatitis C Virus: implications for Direct-Acting Antiviral Use. | Drugs 20170701 |
Metabolism and Disposition of Pan-Genotypic Inhibitor of Hepatitis C Virus NS5A Ombitasvir in Humans. | Drug metabolism and disposition: the biological fate of chemicals 20160801 |
Ombitasvir/Paritaprevir/Ritonavir: A Review in Chronic HCV Genotype 4 Infection. | Drugs 20160801 |
Interferon-free therapy for hepatitis C: The hurdles amid a golden era. | Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver 20150901 |
Ombitasvir/paritaprevir/ritonavir and dasabuvir tablets for hepatitis C virus genotype 1 infection. | The Annals of pharmacotherapy 20150501 |
Dasabuvir : a new direct antiviral agent for the treatment of hepatitis C. | Expert opinion on pharmacotherapy 20150301 |
An update on the management of chronic hepatitis C: 2015 Consensus guidelines from the Canadian Association for the Study of the Liver. | Canadian journal of gastroenterology & hepatology 20150101 |
Discovery of ABT-267, a pan-genotypic inhibitor of HCV NS5A. | Journal of medicinal chemistry 20140313 |
Hepatitis C virus NS5A: tales of a promiscuous protein. | The Journal of general virology 20040901 |
Side effects of alpha interferon in chronic hepatitis C. | Hepatology (Baltimore, Md.) 19970901 |